Minimally Invasive. Reliable Results.

Follow It detects mutations that have prognostic or therapeutic value, even when there is insufficient or unavailable tissue for genomic profiling.

Follow It can be used in cases of metastatic disease, unavailable biopsy, insufficient or exhausted tissue, or poor quality DNA.

Maximize your treatment options with Follow It, a cost-effective and robust assay focused on clinically actionable mutations.

Breast Cancer
GeneTherapeutic OptionsPosition
AKT1 E17
ERBB2 G309, S310, L755, C805, Exon20
ESR1 K303, S463, V534, P535, L536, Y537, D538
PIK3CA R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
Colorectal
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
KRAS G12, G13, A59, Q61, K117, A146
NRAS G12, G13, A59, Q61, K117, A146
PIK3CA R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
Endometrial
GeneTherapeutic OptionsPosition
CTNNB1 D32, S33, G34, S37, T41, S45
PIK3CA R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
POLE Exon9, Exon10, Exon11, Exon12, Exon13, Exon14
Melanoma
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
KIT Exon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
NRAS G12, G13, A59, Q61, K117, A146
GIST
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
PDGFRA N659, R560-E571, D842, L839-Y849
KIT Exon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
Glioma
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
IDH1 R132
IDH2 R140, R172
NSCLC
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
EGFR S492, Exon18, Exon19, Exon20, Exon21
ERBB2 G309, S310, L755, C805, Exon20
KRAS G12, G13, A59, Q61, K117, A146
MET Y1253, Exon13, Exon 14 (-50 to +25), Exon18
Sarcoma
GeneTherapeutic OptionsPosition
GNAS R201
IDH1 R132
IDH2 R140, R172
GenePosition
AKT1E17
ALKT1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275
ARL702H, S741, W742, V716, H875, F877, T878
BRAFQ201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
CTNNB1D32, S33, G34, S37, T41, S45
DDR2L239, I638, S768
EGFRS492, Exon18, Exon19, Exon20, Exon21
ERBB2G309, S310, L755, C805, Exon20
ESR1K303, S463, V534, P535, L536, Y537, D538
GNA11Q209
GNAQQ209
GNASR201
HRASG12, G13, Q61
IDH1R132
IDH2R140, R172
KITExon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
KRASG12, G13, A59, Q61, K117, A146
MAP2K1(MEK1)Q56, K57, K59, D67, C121, P124, P387
MAP2K2(MEK2)F57, Q60, K61, L119
METY1253, Exon13, Exon 14 (-50 to +25), Exon18
NRASG12, G13, A59, Q61, K117, A146
PDGFRAN659, R560-E571, D842, L839-Y849
PIK3CAR88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
POLEExon9, Exon10, Exon11, Exon12, Exon13, Exon14
PTCH1W844, G1093
PTENR130
RETC634, V804, M918
ROS1L2026, G2032
SMOD473, S533, W535
TP53Exon4, Exon5, Exon6, Exon7, Exon8, Exon9
Genes30
Hotspots146
Exons23
Turnaround Time3-5 days
Mutation typesSNVs, deletions and insertions (up to 24bp)
Sensitivity>97.6%
Specificity100%
Assay CutoffBelow .5% VAF
Average Coverage10,000x
Assay Reproducibility94.6%
Sample TypeBlood
Sample Requirement2 x 10 mL of blood in Streck tubes

Benefits

Actionable Results

Reduce ambiguity by targeting only actionable mutations.

Rapid Turnaround Time

Make clinical decisions faster, with accurate reporting in as little as 3 days.

Comprehensive Reports

Review detailed interpretations, current treatment options, and available clinical trials.

Cost-Effective

Reduce the financial burden on healthcare providers and patients with the most cost-effective ctDNA test* on the market.

*defined by geography

Minimally Invasive

A minimally invasive option for biopsy, Follow It can also be used for unavailable biopsy, insufficient tissue, or poor quality DNA.

Accreditation

All Canexia Health assays were developed under full accreditation of the CAP and CLIA.

View Other Solutions

Fusions

Rapid, cost-effective, and clinically actionable, Fusions allows you the flexibility to isolate and interrogate relevant fusions.

Learn About Fusions

Canexia Informatics Platform

Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.

Learn About Our Reports

Comprehensive Reports, Right From Your Lab

Perform world-leading mutation testing for cancer patients, right from your laboratory. From mutation identification to auto-generated clinical reports, Canexia Health’s proprietary platform puts the control back in your hands.

Learn More

 

Canadian Access to Follow It

The Canadian Access Program provides access to Follow It, Canexia Health’s blood-based circulating tumor DNA (ctDNA) next-generation sequencing (NGS) hotspot panel. The program is currently open to oncologists and patients in British Columbia, Ontario, and Quebec, with broader access coming soon.

View Information for Patients